Identification of Response Predictors to Capecitabine/Temozolomide in Metastatic Pancreatic Neuroendocrine Tumors

被引：0
|
作者：
Cives, Mauro [1 ]
Ghayouri, Masoumeh [1 ]
Brelsford, Marjorie [1 ]
Black, Michael [1 ]
Rizzo, Anthony [2 ]
Meeker, Alan [2 ]
Strosberg, Jonathan [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
来源：
PANCREAS | 2016年 / 45卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：473 / 474
页数：2
相关论文
共 50 条
  • [41] Efficacy of oral chemotherapy with capecitabine and temozolomide (CapTem) in metastatic neuroendocrine tumors (NETs): A single-institution experience.
    Smiroldo, Valeria
    Carnaghi, Carlo
    Rimassa, Lorenza
    Personeni, Nicola
    Pressiani, Tiziana
    Bozzarelli, Silvia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [42] First Line Treatment of Metastatic Pancreatic Endocrine Carcinomas with Capecitabine and Temozolomide
    Strosberg, J.
    Choi, J.
    Gardner, N.
    Kvols, L.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 136 - 136
  • [43] Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors
    Kotteas, Elias A.
    Syrigos, Konstantinos N.
    Saif, Muhammad Wasif
    ONCOTARGETS AND THERAPY, 2016, 9 : 699 - 704
  • [44] Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience
    Crespo, Guillermo
    Jimenez-Fonseca, Paula
    Custodio, Ana
    Lopez, Carlos
    Carmona-Bayonas, Alberto
    Alonso, Vicente
    Navarro, Miguel
    Aller, Javier
    Sevilla, Isabel
    Grande, Enrique
    Gajate, Pablo
    Alonso-Gordoa, Teresa
    Matos, Ignacio
    Capdevila, Jaume
    Nieto, Beatriz
    Barriuso, Jorge
    FUTURE ONCOLOGY, 2017, 13 (07) : 615 - 624
  • [45] Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors
    Hauser, Haley
    Gerson, Daniela Shveid
    Reidy-Lagunes, Diane
    Raj, Nitya
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (12)
  • [46] Pancreaticoduodenectomy and metastasectomy for metastatic pancreatic neuroendocrine tumors
    Chawla, Akhil
    Williams, Richelle T.
    Sich, Nicholas
    Clancy, Thomas
    Wang, Jiping
    Ashley, Stanley
    Pezzi, Christopher
    Swanson, Richard
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 118 (06) : 983 - 990
  • [47] Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors
    Haley Hauser
    Daniela Shveid Gerson
    Diane Reidy-Lagunes
    Nitya Raj
    Current Treatment Options in Oncology, 2019, 20
  • [48] Capecitabine Temozolomide Efficacity and Tolerability in Metastatic Neuroendocrine in G2 Neurendocrine Neoplasm
    Bengueddach, A.
    Kehili, H.
    Allaoui, M.
    Benaoum, A.
    Tidjane, A.
    Boudjene, N.
    Tabeti, B.
    Mina, K.
    Larbi, H.
    Yamouni, M.
    NEUROENDOCRINOLOGY, 2019, 108 : 141 - 141
  • [49] Feasibility of Combining Capecitabine and Temozolomide With Yttrium 90 Radioembolization (CapTemY90) for Intermediate-Grade Metastatic Neuroendocrine Tumors
    Soulen, Michael C.
    Teitelbaum, Ursina
    Metz, David
    Mondschein, Jeffrey I.
    Giantonio, Bruce
    Stavropoulos, S. William
    Evans, Tracy
    Damjanov, Nevena
    PANCREAS, 2016, 45 (03) : 482 - 482
  • [50] First-line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide
    Strosberg, J. R.
    Choi, J.
    Gardner, N.
    Kvols, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345